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Abstract
Background Wide resection with tumor-free margins is
necessary in soft-tissue sarcomas to minimize local recur-
rence and to contribute to long-term survival. Information
about treatment outcome and prognostic factors of adult
sarcoma requiring chest wall resection (CWR) is limited.
Methods Sixty consecutive patients were retrospectively
studied for overall survival (OS), local recurrence-free
survival (LRFS), and disease-free survival (DFS). Twenty-
one prognostic factors regarding survival were analyzed by
univariate analysis using the Kaplan-Meier method and the
log-rank test.
Results With a median survival of 2.5 years, the OS was
46% (33%) at 5 (10) years. The LRFS was 64% at 5 and
10 years, and the DFS was 30% and 25% at 5 and 10 years.
At the end of the study period, 26 patients (43%) were
alive, of which 20 patients (33%) had no evidence of dis-
ease and 40 patients (67%) had no chest wall recurrence. In
the group of 9 patients with a radiation-induced soft-tissue
sarcoma, the median survival was 8 months. Favorable
outcome in univariate analysis in OS and LRFS applied for
the low-grade sarcoma, bone invasion, and sternal resec-
tion. For OS only, age below 60 years and no radiotherapy
were significant factors contributing to an improved sur-
vival. CWR was considered radical (R0) at the pathological
examination in 43 patients. There were 52 patients with an
uneventful recovery. There was one postoperative death.
Conclusions CWR for soft-tissue sarcoma is a safe sur-
gical procedure with low morbidity and a mortality rate of
less than 1%. With proper patient selection acceptable
survival can be reached in a large group of patients. Care
must be given to patients with radiation-induced soft-tissue
sarcoma who have a significantly worse prognosis.
Introduction
Soft-tissue sarcomas (STS) account for approximately 1%
of all malignancies in adults. STS involving the chest wall,
ribs, or sternum and overlying soft tissue are rare. In a large
series of 437 STS patients without metastases, only 17
were located in the chest wall [1].
STS are best treated by wide local excision and radio-
therapy [2], which means that most of the STS of the chest
wall need a full-thickness chest wall resection (CWR),
perhaps in combination with skeletal reconstruction and
soft tissue coverage, to obtain negative margins. Surgical
treatment may be preceded or followed by radiotherapy
according to local protocols, especially when narrow
margins are expected or confirmed in the pathological
specimen. There is no indication for (neo-) adjuvant
chemotherapy except in prospective randomized trials.
The etiology of a STS is unknown, except in those
patients who were treated in the past with radiotherapy for
breast cancer or Hodgkin’s disease. The cumulative
radiotherapy-induced STS (RISTS) incidence is reported to
be 0.07% at 5 years, 0.27% at 10 years, and 0.48% at
15 years after radiotherapy treatment [3].
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Information about treatment and prognosis of adult STS
located in the chest wall is limited, especially in cases with
a full-thickness CWR. Only a few series are published in
which the patients were collected over decades. In some of
these series a substantial number of patients are children or
adolescents with so-called small-cell sarcomas for whom
the preferred treatment is salvage surgery after
chemotherapy.
The aim of this study was to describe the factors that
influence prognosis in adult STS patients in whom a CWR
was performed. A relatively large group of these patients
have been treated at our institute and therefore our expe-
rience can contribute to the treatment of patients
worldwide.
Methods
A retrospective study was performed using a database of
229 consecutive patients surgically treated at the Daniel
den Hoed Cancer Center with a CWR for a tumor or a
radiation ulcer of the chest wall between 1986 and 2006.
Sixty-six patients were identified as having a soft-tissue
tumor. Because of the standard primary treatment of che-
motherapy, Ewing’s and other so-called small-cell sarco-
mas were excluded from this study (n = 6). Two patients
developed a local recurrence treated by a second CWR:
only the first CWR is included in this study.
A CWR was defined as a resection of at least one costa
and/or the sternum or a wide soft-tissue resection requiring
reconstruction (Fig. 1). If necessary, several types of inlays
were used for skeletal reconstruction during the 20 years of
this study. The first few years homologous dura mater was
used (Lyodura), later replaced by polyurethane (Neuro-
patch) as an artificial inlay. In some cases polyglactine
(Vicryl) was used. Patients operated on after 2004
received a double-layer polypropylene-PTFE mesh (Com-
posix). Standard soft-tissue reconstruction was performed
with a pedicled omentoplasty, unless primary closure could
be established.
Patient demographics, pathology records, data on the
surgical and (neo-) adjuvant treatment, postoperative
morbidity, mortality, involvement of the resection margins,
and length of follow-up were retrieved from the original
patient files. Surgical aspects of the CWR technique per-
formed in our hospital have been described earlier [4].
The end points of this study were overall survival (OS),
disease-free survival (DFS), and local recurrence-free sur-
vival (LRFS). Univariate analysis was performed using the
Kaplan-Meier method, the log-rank test, and the univariate
Cox proportional hazards model. The outcome of patients
who had postoperative radiotherapy in different subgroups
was also studied: all patients excluding RISTS (n = 9),
because in this group radiotherapy was no longer possible;
all patients excluding borderline tumors (n = 14), because
these patients potentially do not develop metastases; and
patients with free (R0) and involved (R1 and R2) resection
margins. Significance was set at p B 0.05. All the statis-
tical analyses were performed using Stata version 9.2 (Stata
Corporation, College Station, TX, USA).
Results
Sixty consecutive patients met the inclusion criteria of this
study. There were 24 males and 36 females, ranging in age
from 21 to 91 years. All but four patients underwent CWR
with curative intent.
Two groups of patients were distinguished according to
the grade of their tumor [5]. The low-grade group (n = 22)
included grade I STS and patients with a borderline tumor
like desmoid tumors and dermatofibrosarcoma protuberans.
The high-grade group (n = 38) consisted of grade II and III
STS, including 9 patients with a radiation-induced STS
(RISTS).
In 11 patients the CWR consisted of an extended soft-
tissue excision and reconstruction. In 27 patients three or
more costae were removed. In 13 patients the CWR was
performed including a (sub-) total sternectomy. In 13
patients the chest wall did not need to be reconstructed
after the resection because the bony defect was too small.
In some cases the defect was located under the scapula
securing sufficient rigidity of the thorax. In 16 patients the
Fig. 1 High-grade sarcoma of
the anterior chest wall treated by
anterior chest wall resection and
subtotal sternectomy followed
by chest wall reconstruction
(artificial inlay, pedicled
omentoplasty, and meshed split
skin graft)
64 World J Surg (2011) 35:63–69
123
overlying soft tissue needed reconstruction and/or skin
transplantation.
At pathological examination bone invasion was seen in
23 patients. The CWR was considered radical with free
resection margins (R0) in 43 patients. In 10 patients the
CWR was microscopically irradical with involved resec-
tion margins (R1 resection), and in 7 patients a palliative
resection was performed leading to gross involvement of
tumor in the margins (R2 resection).
Sixteen patients, all in the high-grade STS group, had
postoperative radiotherapy. None of the patients received
chemotherapy.
There were 52 patients with an uneventful recovery or
minor complications and 8 patients with serious postoper-
ative complications. One patient with serious lung com-
plications from ARDS required long-lasting artificial
ventilation. Another patient developed pneumonia fol-
lowed by cardiac failure with a fatal outcome. The artificial
inlay for chest wall stabilization was removed in three of
five patients after partial necrosis and subsequent infection
of the wound.
The median follow-up for all patients was 1.7 years
(range = 2–247 months), and for the patients alive at the
end of the study it was 2.7 years (range = 4–247 months).
Median survival was 2.5 years. Overall survival (OS), local
recurrence-free survival (LRFS), and disease-free survival
(DFS) were 46, 64, and 30% at 5 years and 33, 64, and 25%
at 10 years, respectively. At the end of the study period, 26
patients were alive, of which 20 patients had no evidence of
disease and 40 patients had no local recurrence.
The outcome of the statistical analysis for factors with a
positive influence on survival is presented in Table 1. In
univariate analysis regarding OS and LRFS, a low-grade
sarcoma, bone invasion, and sternal resection lead to a
favorable prognosis (Fig. 2). Younger age (\60 years) and
no postoperative radiotherapy are favorable prognostic
factors for the OS. Although resection margin was not a
significant factor, this margin could be difficult to confirm
in some cases with very diffuse or multifocal tumors, like
angiosarcomas. This so-called clinical radicality was a
significant factor for LRFS. The difference in survival
curves for curative and palliative CWR just did not reach a
significant value (p = 0.051).
The effect of postoperative radiotherapy was studied
separately in the following groups: (1) all patients without
a RISTS, (2) all patients with a borderline tumor, (3) all R0
margins, and (4) all R1 and R2 resection margins. OS
remained significantly improved for all 51 patients without
RISTS and all patients without a borderline tumor receiv-
ing radiotherapy (Table 2).
Local recurrences were seen in 20/60 patients (33%); in
16/38 patients (42%) with a high-grade sarcoma and 6/22
patients (27%) with a low-grade sarcoma. All recurrences
occurred within 12 months, except one patient with a high-
grade STS (22 months). The median time to local recur-
rence for RISTS was 4 months. Two of the patients with a
low-grade sarcoma underwent a second CWR for recurrent
disease and remained free of disease until the end of the
study period.
Distant metastases developed in 33 patients (48%). Of
these patients only four had nonborderline low-grade STS.
Four patients underwent a CWR for palliative reasons.
They survived 5, 11, 17, and 28 months, three of them with
adequate local tumor control.
In the 9 patients with a RISTS (high-grade), the median
survival was 8 months. Two patients who had a palliative
CWR for RISTS lived 11 and 17 months and the second
patient developed a local recurrence after 11 months.
Discussion
Our series of 60 patients with STS requiring CWR had a
5-year survival rate of 46%. High-grade tumors had a sig-
nificantly worse prognosis (5-year OS = 23%) compared to
low-grade STS (5-year OS = 85%). The morbidity rate was
acceptably low, with one case of in-hospital mortality.
Most CWRs for sarcomas are performed in chondro-
sarcoma patients [6–9]. These chondrosarcomas are often
low-grade tumors and therefore have a relatively good
prognosis. In patients with low-grade STS, a 5-year OS of
67-80% has been described [6, 8–10]; in our study a 5-year
OS of 85% was obtained. In the high-grade patient group,
the OS is obviously worse, with the 5-year OS varying
from 7 to 59% [7, 11–13]. Our study showed for all
patients a 10-year OS of 33%, which is much lower than
the 67-80% reported in literature [6, 14], with no 10-year
survivors in the high-grade STS group. These different
outcomes can be explained only by selection bias.
Current literature provides hardly any data for prog-
nostic factors other than tumor grade; our study’s analysis
can provide surgeons with more data to make an evidence-
based decision for their future patients (Table 3). Distinctly
negative prognostic factors that reached significance in
univariate analysis for overall, local recurrence-free, and
disease-free survival were pathological grade II/III (for all
p \ 0.0001 and confirmed by others [13, 14]), no sternal
resection, and no tumor invasion in bones confirmed by
pathological examination. Since tumor grade is a well-
accepted prognostic factor in sarcoma surgery, we could
expect this outcome. In our opinion, there is no logical
explanation for bone invasion and sternal resection as
prognostic favorable factors. Perhaps some primary (non-
osteo-) sarcomas of the bone have a better outcome than
soft-tissue sarcomas. However, in this retrospective study
we were unable to identify sarcomas as primary bone
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sarcomas or not. Other factors that might influence prog-
nosis are radical resection [10, 12, 14] (confirmed in our
series only for LRFS in the clinical radical group), tumor
size less than 5 cm [14], age [10] (in our series for OS),
synchronous metastases [10], and local recurrence [10],
although the latter prognostic factor could not be confirmed
in another study [12].
The best results in STS surgery in the extremities are
seen in patients with a R0 resection. The margin for sar-
coma resection is the subject of current discussion and at
present 2 cm is considered to be sufficient [2].Neverthe-
less, when the tumor invades the bony chest wall, this
margin will not be reached at the inner side. Therefore, a
minor margin is accepted as radical here, even when tumor
is seen at the level of the pleura. If the resection margin is
not free in its tangential way, the need of re-resection is
questionable, since no statistical difference in outcome was
found between pathological radical (R0) and irradical (R1
and R2) CWR (5-year OS of 25 and 20%, respectively, in
the high-grade group).
Table 1 Prognostic factors for survival of 60 patients with chest wall resection for soft tissue sarcoma and chondrosarcoma
Covariate (n =) Overall survival Local recurrence-free survival
HR 95% CI HR p HR 95% CI HR p
Gender Female (36) 1 0.32–1.32 0.23 1 0.17–1.36 0.16
Male (24) 0.65 0.48
Age \60 years (40) 1 1.19–4.68 0.01 1 0.34–2.70 0.93
C60 years (20) 2.36 0.96
Indication Curative (56) 1 0.95–7.93 0.051 1 0.46–8.71 0.35
Palliative (4) 2.75 2.00
Diametera B5 cm (27) 1 0.71–2.91 0.32 1 0.35–2.37 0.86
[5 cm (30) 1.43 0.91
Resection Soft tissue (11) 1 0.21–1.10 0.08 1 0.14–1.14 0.08
Bone/soft tissue (49) 0.48 0.40
Number of costae 1, 2 (33) 1 0.35–1.42 0.33 1 0.22–1.55 0.27
3, 4, 5 (27) 0.71 0.58
Sternum resection No (47) 1 0.046–0.54 0.001 1 0.02–1.18 0.04
Yes (13) 0.16 0.16
Lung resection No (55) 1 0.36–3.90 0.79 1 0.28–5.26 0.81
Yes (5) 1.18 1.20
Reconstruction bone No (13) 1 0.28–1.30 0.19 1 0.22–1.72 0.35
Yes (47) 0.60 0.62
Reconstruction soft tissue No (44) 1 0.86–3.88 0.11 1 0.57–4.52 0.37
Yes (16) 1.83 1.60
Grade I (22) 1 4.57–82.03 \0.0001 1 1.62–31.19 0.003
II/III (38) 19.36 7.10
Bone invasion (pathol) No (37) 1 0.21–0.95 0.03 1 0.06–0.78 0.01
Yes (23) 0.45 0.22
Radical (pathol) No (17) 1 0.80–3.30 0.18 1 0.55–3.97 0.43
Yes (43) 1.62 1.48
Radical (clinical) No (20) 1 0.27–1.09 0.08 1 0.12–0.80 0.01
Yes (40) 0.54 0.31
Radiotherapyb No (44) 1 0.12–4.58 0.02 1 0.73–4.94 0.18
Yes (16) 2.26 1.90
Complication No (47) 1 0.51–2.52 0.75 1 0.21–2.48 0.60
Yes (13) 1.14 0.72
Complication serious No (52) 1 0.30–2.44 0.77 1 0.22–4.22 0.97
Yes (8) 0.85 0.97
a Data of three patients missing
b See also Table 2
66 World J Surg (2011) 35:63–69
123
OS in all patients with postoperative radiotherapy is sig-
nificantly worse (p = 0.02), but LRFS is not (p = 0.18).
This finding is in contrast with the results for extremity
sarcomas, in which radiotherapy improves local control but
not the overall survival [15, 16]. It has also been found that
prognosis of chest wall sarcomas is similar to that of
extremity sarcomas [11]. These different outcomes are
explained probably by selection bias. The 60 selected
patients in our study may be an unfavorable group. This
remarkable result was further studied in subgroups of
patients who did or did not have radiotherapy. Table 2 shows
that there was no difference between the R0 and R1/2 groups.
The OS remained significant for all 51 patients without
RISTS and for all patients without borderline tumors. These
findings are an important contribution to the existing litera-
ture concerning the role of radiotherapy in CWR.
A radical resection is advised only for chondrosarcomas:
the 5-year survival rate was 100% for R0 resections com-
pared to 50% for irradical resections [8].
In the literature, complication rates after CWR for STS
are very low and comparable with our complication rate of
12%, including one postoperative death. A postoperative
death was also reported in another series of 16 patients [9,
13]. The risk for adverse events is lower than that for CWR
for recurrent breast cancer [9]. The reason for this is
probably the higher number of ulcerating tumors in breast
cancer patients, leading to an increased risk for infectious
complications [17].
In our series the prognosis for CWR in radiation-
induced STS was poor compared to other series. The
overall survival of 9 patients in our study (8 patients after
breast cancer and 1 patient after Hodgkin’s disease) ranged
between 2 and 26 (median = 8) months. Other reports
show an actuarial 5-year survival of 36%, and after a
median follow-up of 30 months, a 5-year survival of 48%
[3, 18]. A possible explanation for our relatively poor
outcome could be the extensive tumor growth in our group
of patients and the fact that they did not receive radio-
therapy after CWR. Based on the results of our series, one
could argue that a CWR is indicated in this group of
patients only as a palliative procedure.
Reconstruction of the chest wall for stabilization is carried
out for defects of more than one rib, although even larger
defects on the posterior side do not require reconstruction.
For reconstruction of the rigid chest wall several biologic
(absorbable; Lyodura,) and synthetic materials (absorb-
able such as Vicryl and Dexon, and nonabsorbable such
as Prolene, Marlex, Gore-Tex) and even combinations
are available. Even a rigid reconstruction can be used (metal,
methylmethacrylate). The best method is still being debated
but the general thought is that absorbable materials do not
pose wound problems in case of infection and the recon-
struction is easier and faster. Nonrigid reconstruction is
sufficient to temporarily stabilize the chest wall, enhance the
respiratory function, and help the recovery of the patient.
After CWR, lung function is reduced by about 10% [9].
The result of this study (and the experience in the entire
series of 229 patients [17]) is that our method of recon-
struction is safe and that a time-consuming skeletal recon-
struction with rigid materials like steel or bone cement in
combination with Marlex  is not necessary [6, 9].
Fig. 2 Overall survival of chest wall resection for soft tissue sarcoma
and chondrosarcoma by grade, bone invasion, and sternal resection
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Conclusion
Despite the fact that most sarcomas of the chest wall are
voluminous tumors, a chest wall resection is a safe surgical
procedure with low morbidity and a mortality rate of less
than 1%. After diagnosing a patient with a tumor of the
chest wall, the patient’s case should be discussed by a
multidisciplinary group, including a surgeon, pathologist,
radiologist, radiotherapist, medical oncologist, and plastic
surgeon, to confirm optimal treatment planning and
reconstructive possibilities. Even in isolated local recur-
rences, a second CWR can be considered. In patients with
Table 2 Radiotherapy as a prognostic factor in subgroups of patients with chest wall resection for soft tissue sarcoma and chondrosarcoma
Covariate Radiotherapy Overall survival Local recurrence-free survival
HR 95% CI HR p HR 95% CI HR p
Exc RISTSa (n = 51) No 1 0.13–5.32 0.02 1 0.84–7.11 0.09
Yes 2.45 2.44
Exc Borderlineb (n = 46) No 1 1.17–5.28 0.01 1 0.74–5.22 0.17
Yes 2.49 1.96
RO3 (n = 43) No 1 0.59–5.90 0.28 1 0.23–5.77 0.86
Yes 1.86 1.16
R1 and R2c (n = 17) No 1 0.92–6.62 0.06 1 0.69–7.71 0.16
Yes 2.46 2.30
a All patients excluding radiation-induced soft tissue sarcoma
b All patients excluding borderline tumors
c Resection margin is free (R0), microscopically involved (R1), grossly involved (R2)
Table 3 Review of the literature of chest wall resection for soft tissue sarcoma and chondrosarcoma
Author (year) [Ref] n % Overall survival and (disease-free survival) Remarks
5-year 10-year
Perry (1990) [12] 28 59 (40) Only high-grade sarcomas, including
recurrent sarcomas
Gordon (1991) [11] 149 90 low-grade
49 high-grade
Burt (1992) [10] 88 64 Chondrosarcomas
Martini (1996) [7] 80 Median follow-up 17 years
64 Curative low-grade
7 Curative high-grade
Chapelier (1997) [18] 15 48 (27) Including radiation-induced sarcomas
Median follow-up 30 months
Sabanathan (1997) [6] 22 67 Chondrosarcomas
Athenassiadi (2001) [19] 8 33
Bricolli (2002) [9] 16 86 Chondrosarcomas
Median follow-up 54 months
Fong (2004) [8] 24 92 Chondrosarcomas
100 radical
50 irradical
Kirova (2005) [3] 8 Median 40 m Radiation-induced (osteo) sarcomas
Gross (2005) [14] 55 87 (75) 80 (64) 28 primary and 27 recurrent sarcomas
Pfannschmidt (2006) [13] 25 57 Median survival all patients 100 months
Median survival high-grade 36 months42 high-grade
van Geel (this series) 60 46 (28) 30 (25) Median follow-up 1.7 years and survival 2.5 years
85 (72) low-grade 85 (72)
23 (10) high-grade 6 (–)
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systemic disease, a CWR can be considered for palliative
reasons, for example, to maintain local tumor control in
case of substantial tumor burden in the chest wall.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
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